Loading
NASDAQHealthcareBiotechnology
Latest quote
$72.22
−$1.39 · -1.89%
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing and commercializing innovative therapies, primarily focusing on ocular conditions. Its leading investigational drug, TP-03, a novel treatment currently in Phase III trials, is being developed to address blepharitis specifically caused by Demodex mite infestations, as well as meibomian gland disease. Beyond this, Tarsus is also progressing TP-04 for rosacea and TP-05, which targets Lyme disease prevention and aims to reduce community-level malaria. A core element of its development strategy involves lotilaner, a compound utilized to tackle a variety of human diseases across diverse therapeutic areas, encompassing eye care, dermatology, and other medical fields. Established in 2016, the company maintains its headquarters in Irvine, California.
Latest quote
$72.22
−$1.39 · -1.89%
After-hours
$72.22
$0.00 · 0.00%
Oct 8, 5:46 PM ET
Regular session · ET · Market data may be delayed.
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing and commercializing innovative therapies, primarily focusing on ocular conditions. Its leading investigational drug, TP-03, a novel treatment currently in Phase III trials, is being developed to address blepharitis specifically caused by Demodex mite infestations, as well as meibomian gland disease. Beyond this, Tarsus is also progressing TP-04 for rosacea and TP-05, which targets Lyme disease prevention and aims to reduce community-level malaria. A core element of its development strategy involves lotilaner, a compound utilized to tackle a variety of human diseases across diverse therapeutic areas, encompassing eye care, dermatology, and other medical fields. Established in 2016, the company maintains its headquarters in Irvine, California.
Day range
Current $72.22
52-week range
Current $72.22
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
82
Deep Value
Sentiment
52
Mixed
Risk
51
Elevated Risk
Momentum
40
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing and commercializing innovative therapies, primarily focusing on ocular conditions. Its leading investigational drug, TP-03, a novel treatment currently in Phase III trials, is being developed to address blepharitis specifically caused by Demodex mite infestations, as well as meibomian gland disease. Beyond this, Tarsus is also progressing TP-04 for rosacea and TP-05, which targets Lyme disease prevention and aims to reduce community-level malaria. A core element of its development strategy involves lotilaner, a compound utilized to tackle a variety of human diseases across diverse therapeutic areas, encompassing eye care, dermatology, and other medical fields. Established in 2016, the company maintains its headquarters in Irvine, California.
Day range
Current $72.22
52-week range
Current $72.22
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 451.36M USD | 182.95M USD | 17.45M USD | 25.82M USD | 57.03M USD |
| Cost of goods sold | 30.68M USD | 12.83M USD | 1.59M USD | 955K USD | 2.08M USD |
| Gross profit | 420.68M USD | 170.13M USD | 15.85M USD | 24.86M USD | 54.95M USD |
| Research and development | 64.32M USD | 53.39M USD | 50.31M USD | 42.62M USD | 41.71M USD |
| Selling, general, and administrative | 427.32M USD | 237.31M USD | 108.7M USD | 44.95M USD | 25.4M USD |
| Operating expenses | 491.65M USD | 290.7M USD | 159.01M USD | 87.57M USD | 67.11M USD |
| Interest income | 15.75M USD | 15.01M USD | 10.34M USD | 3.5M USD | 36K USD |
| Interest expense | 8.94M USD | 7.45M USD | 3.23M USD | 2.06M USD | — |
| Depreciation and amortization | 1.82M USD | 1.23M USD | 877K USD | 326K USD | 312K USD |
| Operating income | −70.97M USD | −120.57M USD | −143.16M USD | −62.71M USD | −12.16M USD |
| Net income | −66.42M USD | −115.55M USD | −135.89M USD | −62.09M USD | −13.83M USD |
Company facts updated Oct 8, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$103
42.62% upsideFunds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI96.47M0.00%2.3T USD0.03%$379.56-0.39%
iShares Russell 2000 ETFIWM80.94M0.10%78.56B USD0.19%$277.57-0.05%
Vanguard Extended Market ETFVXF34.19M0.04%95.4B USD0.05%$233.13-0.15%
iShares Russell 2000 Growth ETFIWO28.82M0.21%14.25B USD0.24%$353.47-0.53%
iShares Biotechnology ETFIBB22.98M0.22%10.4B USD0.44%$200.48-1.41%
Invesco Pharmaceuticals ETFPJP18.22M3.35%542.27M USD0.58%$120.96-0.47%
Vanguard Russell 2000 ETFVTWO17.87M0.10%18B USD0.06%$112.1-0.10%
Schwab U.S. Small-Cap ETFSCHA14.98M0.07%21.7B USD0.03%$32.66+0.15%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOiShares Biotechnology ETFIBBInvesco Pharmaceuticals ETFPJPVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
